Avidity Biosciences Inc
Închisă
SectorSănătate
15.05
Rezumat
Modificarea prețului
24h
Minim
15.05
Maxim
15.05
Venit | -63M -237M |
|---|---|
Vânzări | -12M 860K |
EPS | -1.27 |
Marjă de profit | -27,569.884 |
Angajați | 511 |
EBITDA | -59M -232M |
Recomandări | Neutru |
|---|---|
Prognoză pe 12 luni | -0.1% downside |
Capitalizare de piață | -9B 2.3B |
|---|---|
Deschiderea anterioară | 15.05 |
Închiderea anterioară | 15.05 |
Scor tehnic
By Trading Central
Încredere
Strong Bearish Evidence
Avidity Biosciences Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Avidity Biosciences Inc Așteptări
Obiectiv de preț
By TipRanks
-0.1% jos
Prognoză pe 12 luni
Medie 72.75 USD -0.1%
Maxim 75 USD
Minim 72 USD
În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAvidity Biosciences Inc - Dist în ultimele 3 luni.
Date financiare
$
Despre Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.